ISSAR Pharma

Issar's peptide treatment therapy solution for dermatology

Peptides in Dermatology: A Therapeutic Potential in Future?

ISSAR is bringing hope for a stigma-free experience for patients affected
with psychologically distressing skin conditions.

ISSAR has paved its very own pathway for peptides as therapeutics for skin conditions. Their proven scientific expertise has helped them introduce India’s first peptide molecule, Novoskin®, for a skin condition called Vitiligo.

 

Therapeutic potential of peptides in dermatology

A maximum number of complaints worldwide, arise due to skin conditions. As per a 2010 Global Disease Burden study, skin diseases were among the top ten widespread diseases and the fourth most frequent cause of non-fatal disease burden worldwide. These conditions have been observed to have the most stigmatising effects on an individual, resulting in low self-esteem and extreme psychological distress.

There is significant escalation in the understanding and application of peptides as therapeutics for skin conditions. Specifically, peptides with antimicrobial properties and those associated with inflammatory processes serve as potential therapeutic agents for conditions like psoriasis, dermatitis, and vitiligo.

Cyclic peptides perform a wide range of biological functions and can be modified both synthetically and genetically to improve skin permeability and structural stability. Therefore, they provide excellent drug leads to achieve the desired action.

 

ISSAR’s Novoskin® for Vitiligo

Vitiligo is an autoimmune disease that causes destruction of melanocytes in the body, manifesting as depigmented macules and patches on the skin.

The global prevalence of this condition has increased from 0.5%-3%, equally affecting individuals of all ages, races and genders.

ISSAR has developed a topical peptide based formulation of vitiligo called Novoskin®.

Novoskin® lotion is a repigmenting agent. It works by stimulating migration of skin cells (melanocytes) from the area of skin surrounding the vitiligo patch. This in turn causes the production of melanin (skin darkening pigment) and restores the skin colour.

 

ISSAR’s Xylentra® for burn wounds

Burns are considered as one of the leading causes of death worldwide. Everyday 30,000 people are affected with burns, which accounts to over 11 million people globally every year.

Xylentra® is designed as a broad-spectrum antibacterial cream for the treatment of burn wounds. It contains an active drug substance called Genopep®. It is 23-amino acid peptide with three specific amino acids: Alanine (A), Phenylalanine (F), and Lysine (K).

Xylentra® creams helps in stimulating fibroblast and keratinocyte growth factors and inhibits the growth of commonly occurring bacteria including the most resistant forms. Thus, it controls infection without producing side effects. It provides an optimum physiological environment for spontaneous healing without further damage to viable tissues.

 

ISSAR’s Soriacare® for Psoriasis

Psoriasis is a chronic, inflammatory, autoimmune disorder characterized by dry, raised, inflamed scaly patches on the skin.

It can occur equally in both males and females, affecting all age groups, most commonly between 50-69 years of age. The global prevalence of psoriasis ranges from 0.09% to 11.14%.

Soriacare® is a novel, non-biologic, non-steroidal, synthetic, small decapeptide consisting of 10 amino acids. It has a dual mechanism of action targeting the Vascular Endothelial Growth Factor (VEGF) and IL17/23.

Soriacare® binds to the VEGF and blocks the binding of VEGF to its receptor, thus exhibiting anti-angiogenesis and anti-inflammatory action. The pre-clinical trials provided evidence of the possibility to treat inflammatory skin diseases such as Psoriasis by subcutaneous administration of an angiogenic compound.